Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
From 17 March, 2020 to 29 april, 2020
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2020
Report date:
2020

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 442B (Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA)
Version / remarks:
adopted 25 June 2018
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Type of study:
mouse local lymph node assay (LLNA): BrdU-ELISA

Test material

Reference
Name:
Unnamed
Type:
Constituent
Test material form:
solid

In vivo test system

Test animals

Species:
mouse
Strain:
Balb/c
Sex:
female
Details on test animals and environmental conditions:
Test System: BALB/cMice
Scientific Name : Mus musculus
Justification: As this test system show good sensitization response to the positive control.
Source: Animal Breeding, RCC Laboratories India Private Limited, Genome Valley, Turkapally, Shameerpet (Manda!), Ranga Reddy District, Hyderabad - 500 078 India.

Pretest
Total number of Animals used: 8 Females (females were nulliparous and non-pregnant)

Main Study
Number of Animals per Group: 5 Females (females were nulliparous and non-pregnant)
Number of Groups: 6
Total Number of Animals: 30
Age when Treated: 11- 13 Weeks
Body weight when treated : Females: 21.72 to 24.52 g

Identification: By unique cage number and individual animal numbers marked with indelible marker pen on the tail. The animals were marked (towards the tip of tail) with red color for the temporary animal numbers at start of acclimatization. The animals were marked with black color for permanent animal numbers (towards the base of tail) before the start of test item administration.

Randomization: Animals were selected and grouped based on stratified randomization by using body weights. Computerized statistical analysis was used for randomization

Acclimatization: Under laboratory conditions for 07 days, after veterinary examination. Only animals without visible signs of illness were used for the study.

Environment
The animal room was air-conditioned with adequate (above 10) air changes per hour. The air was continuously monitored for temperature and relative humidity. The ranges for room temperature and relative humidity were 22.9 to 24.5°C and 50 to 65%, respectively. The animals were provided with a light cycle of 12 hours light and 12 hours dark.

Accomodation
Individually in Polycarbonate cages (approximate internal dimensions of 214 mm x 154 mm x 138 mm) with paddy husk bedding. Results of analyses for contaminants will be archived at RCC Laboratories India Private Limited.

Enrichment
Tunnels were provided for individually housed animals.

Diet
Teklad Certified Global 14% Protein Rodent Maintenance Diet (Lot Number: 2014C-091719MA) from ENVIGO was provided ad libitum. Results of analyses for contaminants will be archived at RCC Laboratories India Private Limited.

Water
UV purified water was provided ad libitum. Results of bacteriological, chemical and contaminant analyses will be archived at RCC Laboratories India Private Limited.

Study design: in vivo (LLNA)

Vehicle:
dimethyl sulphoxide
Details on study design:
Dose formulation
The dose levels are in terms of the test substance as supplied. The dose formulations were prepared shortly before each dosing. The test substance was formulated in vehicle. The quantity of test substance was mixed with vehicle and the final volume was made up to 1000 µl for each group in a separate micro centrifuge tube. Homogeneity of the test substance in the vehicle was maintained during administration using a vortex mixer.

Note: DMSO (Dimethyl sulphoxide) was used as a vehicle for treatment group (Test substance) whereas acetone+ Olive Oil (4:1) were used as a vehicle for positive control group (Eugenol).

Selection of test substance concentrations for main study
A pretest was conducted to find out the appropriate test substance concentrations for main study. Two Female mice were used for each dose concentration. The dose concentrations used in the pretest are 10%, 25%, 50% and 100%. No mortality was observed at the concentrations of 10%, 25%, 50% and 100%. No clinical signs were observed at the concentrations of 10%, 25%, 50% and 100%. Animals were observed for body weight on Day 1 (prior to test substance application) and Day 6. Ears were observed for erythema on Day 1-6. Ear thickness was measured on Day 1 (pre dose), Day 3 (approximately 48 hours after the first dose) and Day 6. Ear thickness and body weights were well within the normal range and no erythema was observed at the tested concentrations. The doses for the main study was selected based on the results of pretest and were described in an amendment to study plan. Pretest was performed before study initiation date and hence, excluded from statement of GLP. The doses selected for the main study was 10%, 25%, 50% and 100% for low, low mid, high mid and high doses, respectively. Considering the mortality, clinical signs and solubility of the test substance in the vehicle, the highest non-toxic concentration (100%) was selected for the main study.

Treatment
On Day 1, 2 and 3, the formulated test substance was applied to the dorsum of both the ears in a volume of 25 µL/ear using micropipette.

Justification: Dermal application is considered to be an appropriate application method as it is a possible route of human exposure during manufacture, handling and use of the test substance.

Dosing with BrdU
BrdU preparation
200 mg of BrdU was weighed into a tarred glass beaker on a weighing balance. 3 mL of phosphate buffer saline was added to beaker containing BrdU and mixed properly by using glass rod. This was then transferred to a 20 mL volumetric flask. Sufficient quantity of phosphate buffer saline was added to make up the required volume of solution (WN) to 20 mL. This was then transferred back to the beaker and mixed properly. The 10 mg/mL PBS solution containing BrdU was administered intraperitoneally to all the animals at a dose level of 5 mg/animal (0.5 mL/animal) on day 5. The BrdU solution was prepared freshly before administration.

Observation
MortalityNiability
Twice daily during the acclimatization period and during treatment and observation days, once on day of receipt and sacrifice.

Body Weights
On test days l (prior to test substance application) and 6 (Necropsy).

Clinical Signs
Once daily during the acclimatization period, at least twice daily approximately at 1st and 4th hours after test substance administration and on test day 1- 3, day 5 and once on day 4 and day 6.

Skin Reaction (Both Ears) Ear thickness
The skin reaction was assessed on days 1- 6 according to the numerical scoring system. Ear thickness was measured on Day I (pre-dose), Day 3 (approximately 48 hours after the first dose) and Day 6.

Pathology
Necropsy
All the treated animals were sacrificed at the end of the observation period by carbon dioxide asphyxiation in euthanasia chamber. Gross/macroscopic pathological changes were observed and recorded. The auricular lymph nodes were excised from both ears of all the animals. The auricular lymph nodes were weighed and stored in ice-chilled Phosphate Buffer Saline (PBS) and kept in deep freezer (-20·C) until further processing. No organ and tissues were retained

6BrdU: ELISA
The incorporation of BrdU into lymph node cells was determined using a commercial cell proliferation assay kit (Roche Diagnostics). The assay procedure was as follows:

Lymph Node Cell (LNC) suspension Preparation
• The collected auricular lymph nodes were crushed using small pestle.
• 0.3 ml of PBS (Phosphate Buffer Saline) was added and the suspension was collected in a centrifuge tube.
• This suspension was pass through a nylon mesh (70µm). The volume of cell suspension was made up to 15 ml with PBS.

Assay Flow (BrdU- ELISA)
1. LNC suspension was centrifuged at 2000 rpm for ten minutes
2. ¾ th of supernatant solution was removed.
3. The cell suspension (100 µL) was added to Micro well plate (3 replicates /sample) and thoroughly mixed. This micro well plate was dried completely in a hot air oven at 45°C.
4. 200 µL of Fix-Denat solution was added to each well and allowed to stand for 30 minutes.
5. Fix-Denat solution was removed completely after 30 minutes.
6. 100 µL of anti-BrdU-POD antibody working solution was added and allowed to react for 1 hour.
7. Anti-BrdU-POD antibody working solution was removed completely after 1 hour.
8. 200 µL of wash solution (PBS) was added and washed the wells by pipetting 10 times. The solution was completely removed and discarded. Same step was repeated twice.
9. 100 µL of TMB (Tetra methyl Benzidine) substrate solution was added and allowed to stand for 15 minutes at room temperature in a dark place.
10. The absorbance was measured at 370 nm using spectramax reader.

Calculation
Stimulation Index (SI) was calculated as follows:
OD values for each test animal/ mean OD values for concurrent Negative control group

Accetability of the assay
The positive control response at an exposure level expected to give an increase in the SI greater than or equal to 1.6 over the negative control.
The SI >14 should be considered to be an excessive response. Induction at this level is considered to be not reproducible.
The SI 2:: 1.6 value of test substance is considered to be a positive response and the test substance a potential skin sensitizer.

Data compilation
Mortality/Viability, Clinical Signs, Skin Reactions, Ear Thickness measurements, Body Weights and Organ Weights were recorded on data sheets. All data generated by the 96-well plate ELISA reader was printed after reading and considered as raw data and excel sheet were used to calculate the Stimulation index. Data from individual animal was reported in tabular form. The Data was reported as mean± SD (standard deviation).
Positive control substance(s):
eugenol (CAS No 97-53-0)

Results and discussion

In vivo (LLNA)

Resultsopen allclose all
Key result
Parameter:
SI
Value:
ca. 1.07
Test group / Remarks:
10% test substance
Key result
Parameter:
SI
Value:
ca. 1.111
Test group / Remarks:
25% test substance
Key result
Parameter:
SI
Value:
ca. 1.119
Test group / Remarks:
50% test substance
Key result
Parameter:
SI
Value:
ca. 3.954
Test group / Remarks:
Positive control
Key result
Parameter:
SI
Value:
ca. 1.154
Test group / Remarks:
100% test substance
Cellular proliferation data / Observations:
Mortality
No mortality was observed in any of the animals treated during experimental period.

Clinical signs
All the animals appeared normal throughout the acclimatization period. All the animals appeared normal throughout the study observation period.

Body weights
The body weight of the animals was within the normal range of variability commonly recorded for this species, strain and age.

Skin reaction
The test substance did not induce any degree of erythema on the both ears of all animals in control and treatment groups on Day 1 to Day 6. Animals in positive control group showed well defined erythema on both the ears on Day 1 to Day 6.

Ear thickness
Ear thickness measurements in treated group animals were comparable with negative control group. Whereas ear thickness was slightly increased in positive control group compared with negative control group.

Macroscopic findings
No abnormalities were observed externally and internally in negative control, low, low mid, high mid and high dose group animals at necropsy. Externally both ears (Bilateral) found reddened, internally the size of the auricular lymph nodes (Bilateral) was enlarged slightly in positive control group at terminal sacrifice.

Organ weight
The size of the auricular lymph nodes was enlarged slightly in positive control group compared to negative control group.

BrdU ELISA results
A BrdU ELISA measurement with cell suspension of Auricular lymph nodes resulted in mean stimulation indexes of 1.070, 1.111, 1.119 and 1.154 at concentrations of 10, 25, 50 and 100%, respectively. Stimulation Index (SI) value of positive control was 3.954 and thus confirmed the validity of the test system.

Conclusion
The Stimulation Index (SI) of animals treated with test substance at concentrations of 10, 25, 50 and 100% was less than 1.6. Hence, the test substance is not a potential skin sensitizer.

Any other information on results incl. tables

Results

Table 1: Mortality, viability and clinical signs

Group

Dose

Animal Number

Sex

Test day

1

2

3

4

5

6

 

 

1

 

0%(NC)

01

Female

1

1

1

1

1

1

1

1

1

1

02

Female

1

1

l

1

1

l

1

1

1

1

03

Female

1

1

1

1

1

1

l

1

1

1

04

Female

l

1

1

1

1

1

1

1

1

1

05

Female

1

1

1

I

1

1

l

1

1

1

 

 

2

 

10%(L)

06

Female

1

1

1

1

1

1

1

1

1

1

07

Female

1

1

I

1

1

1

1

1

1

1

08

Female

1

1

1

1

1

1

I

1

1

l

09

Female

1

1

1

1

1

l

1

1

1

1

10

Female

1

1

I

I

1

1

1

1

I

1

 

 

3

 

25%(LM)

11

Female

1

1

1

1

1

1

1

1

1

1

12

Female

1

1

1

1

1

l

1

1

1

1

13

Female

1

l

1

1

1

1

1

1

1

1

14

Female

1

1

1

1

1

1

1

1

1

1

15

Female

1

1

1

1

1

1

1

1

1

1

 

 

4

 

50% (HM)

16

Female

l

1

1

1

1

1

1

1

1

1

17

Female

1

1

1

1

1

1

l

1

1

l

18

Female

1

1

1

1

1

1

1

1

1

1

19

Female

1

1

1

1

1

l

1

1

l

1

20

Female

1

1

1

1

1

1

1

1

1

1

 

 

5

 

100%

(H)

21

Female

1

1

1

1

1

1

1

1

1

I

22

Female

1

1

I

1

1

1

1

1

1

l

23

Female

1

1

1

1

1

1

1

1

1

1

24

Female

I

1

1

1

1

1

1

1

1

1

25

Female

1

1

I

1

1

1

1

1

1

1

 

 

6

 

25%(PC)

26

Female

1

1

1

1

I

1

1

1

1

1

27

Female

1

1

1

1

1

1

1

1

1

1

28

Female

1

1

1

1

1

1

1

1

1

1

29

Female

1

1

1

1

1

l

1

l

1

l

30

Female

1

1

1

1

1

1

1

1

1

1

Key: %=percentage, l= Normal, NC-Negative Control, L-Low,   LM-Low Mid, HM- High Mid, H-High, PC-Positive Control

No clinical signs were evident in any animal during the acclimatization period.

Table 2: Body weight

 

Group

 

Dose

Animal Number

 

Sex

Test day 1

(pre-treatment)

(g)

Test day 6

(g)

 

 

1

 

 

0% (NC)

01

Female

24.52

25.11

02

Female

22.73

23.85

03

Female

23.10

24.08

04

Female

21.95

23.29

05

Female

22.18

23.27

 

 

2

 

 

10% (L)

06

Female

23.78

25.75

07

Female

22.69

24.41

08

Female

22.50

23.41

09

Female

21.83

23.70

10

Female

22.13

23.89

 

 

3

 

 

25% (LM)

11

Female

23.62

24.70

12

Female

22.75

23.43

13

Female

22.43

23.25

14

Female

21.76

23.84

15

Female

21.91

23.33

 

 

4

 

 

50% (HM)

16

Female

23.29

23.96

17

Female

22.80

24.37

18

Female

22.69

24.33

19

Female

22.15

23.52

20

Female

21.90

22.84

 

 

5

 

 

100% (H)

21

Female

23.24

23.93

22

Female

22.86

24.04

23

Female

22.40

23.74

24

Female

22.19

24.02

25

Female

21.95

23.44

 

 

6

 

 

25% (PC)

26

Female

23.16

24.43

27

Female

22.85

23.80

28

Female

22.22

23.46

29

Female

22.30

23.72

30

Female

21.72

22.95

Key: %= percentage, g=gram, NC-Negative Control, L-Low, LM-Low Mid, HM- High Mid, H-High, PC-Positive Control

Table 3: Skin reactions

Reaction Scores

 

Group

 

Dose

Animal Number

 

Sex

Site ofApplication

Observation Day

1

2

3

4

5

6

 

 

 

 

 

 

 

1

 

 

 

 

 

 

0%

(NC)

 

01

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

02

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

03

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

04

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

05

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

 

 

 

 

 

2

 

 

 

 

 

 

10% (L)

 

06

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

07

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

08

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

09

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

10

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

Key: NC-Negative Control, L-Low.

Reaction Scores

 

Group

 

Dose

AnimalNumber

 

Sex

Site ofApplication

Observation Day

1

2

3

4

5

6

 

 

 

 

 

 

 

3

 

 

 

 

 

 

25%

(LM)

 

11

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

12

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

13

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

14

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

15

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

 

 

 

 

 

 

4

 

 

 

 

 

 

50%

(HM)

 

16

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

17

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

18

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

19

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

20

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

Key: LM-Low Mid, HM-High Mid

Reaction Scores

 

Group

 

Dose

Animal Number

 

Sex

Site of Application

Observation Day

1

2

3

4

5

6

 

 

 

 

 

5

 

 

 

 

 

100%

(H)

21

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

22

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

23

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

24

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

25

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

 

 

 

 

6

 

 

 

 

 

25%

(PC)

26

Female

Right Ear

0

2

2

2

2

2

Left Ear

0

2

2

2

2

2

27

Female

Right Ear

0

2

2

2

2

2

Left Ear

0

2

2

2

2

2

28

Female

Right Ear

0

2

2

2

2

2

Left Ear

0

2

2

2

2

2

29

Female

Right Ear

0

2

2

2

2

2

Left Ear

0

2

2

2

2

2

30

Female

Right Ear

0

2

2

2

2

2

Left Ear

0

2

2

2

2

2

Key: H-High; PC-Positive Control

Table 4: Ear thickness on Day 1

Group

Dose

Animal Number

Sex

Site of Application

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

1

 

 

 

 

 

 

0% (NC)

 

01

 

Female

Right Ear

0.280

 

0.279

 

 

 

 

 

 

0.280±0.0098

Left Ear

0.278

 

02

 

Female

Right Ear

0.297

 

0.296

Left Ear

0.294

 

03

 

Female

Right Ear

0.272

 

0.271

Left Ear

0.269

 

04

 

Female

Right Ear

0.274

 

0.273

Left Ear

0.272

 

05

 

Female

Right Ear

0.283

 

0.282

Left Ear

0.281

 

 

 

 

 

 

2

 

 

 

 

 

 

10%

(L)

 

06

 

Female

Right Ear

0.286

 

0.285

 

 

 

 

 

 

 

0.285±0.0061

Left Ear

0.284

 

07

 

Female

Right Ear

0.291

 

0.290

Left Ear

0.289

 

08

 

Female

Right Ear

0.295

 

0.294

Left Ear

0.292

 

09

 

Female

Right Ear

0.288

 

0.287

Left Ear

0.286

 

10

 

Female

Right Ear

0.302

 

0.301

Left Ear

0.299

Key: mm-Millimeter; NC-Negative Control, L-Low

Group

Dose

AnimalNumber

Sex

Site of Aoolication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

3

 

 

 

 

 

 

25%(LM)

 

11

 

Female

Right Ear

0.294

 

0.293

 

 

 

 

 

 

 

0.300±0.0084

Left Ear

0.291

 

12

 

Female

Right Ear

0.308

 

0.307

Left Ear

0.306

 

13

 

Female

Right Ear

0.312

 

0.311

Left Ear

0.309

 

14

 

Female

Right Ear

0.292

 

0.291

Left Ear

0.289

 

15

 

Female

Right Ear

0.301

 

0.300

Left Ear

0.298

 

 

 

 

 

 

 

4

 

 

 

 

 

 

50% (HM)

 

16

 

Female

Right Ear

0.298

 

0.297

 

 

 

 

 

 

 

0.298±0.0075

Left Ear

0.295

 

17

 

Female

Right Ear

0.309

 

0.308

Left Ear

0.307

 

18

 

Female

Right Ear

0.303

 

0.302

Left Ear

0.301

 

19

 

Female

Right Ear

0.289

 

0.288

Left Ear

0.287

 

20

 

Female

Right Ear

0.297

 

0.296

Left Ear

0.294

Key: mm-Millimeter, LM-Low Mid, HM-High Mid

Group

Dose

AnimalNumber

Sex

Site ofApplication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

5

 

 

 

 

 

 

100%

(H)

 

21

 

Female

Right Ear

0.314

 

0.313

 

 

 

 

 

 

 

0.304±0.0062

Left Ear

0.311

 

22

 

Female

Right Ear

0.299

 

0.298

Left Ear

0.297

 

23

 

Female

Right Ear

0.308

 

0.307

Left Ear

0.305

 

24

 

Female

Right Ear

0.299

 

0.298

Left Ear

0.297

 

25

 

Female

Right Ear

0.307

 

0.306

Left Ear

0.304

 

 

 

 

 

 

 

6

 

 

 

 

 

 

25%

(PC)

 

26

 

Female

Right Ear

0.294

 

0.293

 

 

 

 

 

 

0.299±0.0100

Left Ear

0.292

 

27

 

Female

Right Ear

0.315

 

0.314

Left Ear

0.313

 

28

 

Female

Right Ear

0.304

 

0.303

Left Ear

0.301

 

29

 

Female

Right Ear

0.289

 

0.288

Left Ear

0.287

 

30

 

Female

Right Ear

0.298

 

0.297

Left Ear

0.296

Key: mm-Millimeter, H-High, PC-Positive Control

Table 5: Ear thickness on Day 3

Group

Dose

Animal Number

Sex

Site ofApplication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

I

 

 

 

 

 

 

0% (NC)

 

01

 

Female

Right Ear

0.282

 

0.281

 

 

 

 

 

 

0.282 ± 0.0095

Left Ear

0.279

 

02

 

Female

Right Ear

0.299

 

0.298

Left Ear

0.296

 

03

 

Female

Right Ear

0.275

 

0.274

Left Ear

0.273

 

04

 

Female

Right Ear

0.276

 

0.275

Left Ear

0.274

 

05

 

Female

Right Ear

0.286

 

0.285

Left Ear

0.284

 

 

 

 

 

 

 

2

 

 

 

 

 

 

10%

(L)

 

06

 

Female

Right Ear

0.288

 

0.287

 

 

 

 

 

 

0.287 ± 0.0061

Left Ear

0.286

 

07

 

Female

Right Ear

0.294

 

0.293

Left Ear

0.292

 

08

 

Female

Right Ear

0.297

 

0.296

Left Ear

0.294

 

09

 

Female

Right Ear

0.291

 

0.290

Left Ear

0.289

 

10

 

Female

Right Ear

0.304

 

0.303

Left Ear

0.302

Key: mm-Millimeter; NC-Negative Control, L-Low

Group

Dose

AnimalNumber

Sex

Site of Aoolication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

3

 

 

 

 

 

 

25% (LM)

 

11

 

Female

Right Ear

0.296

 

0.295

 

 

 

 

 

 

0.303± 0.0081

Left Ear

0.294

 

12

 

Female

Right Ear

0.311

 

0.310

Left Ear

0.308

 

13

 

Female

Right Ear

0.314

 

0.313

Left Ear

0.311

 

14

 

Female

Right Ear

0.295

 

0.294

Left Ear

0.292

 

15

 

Female

Right Ear

0.304

 

0.303

Left Ear

0.301

 

 

 

 

 

 

 

4

 

 

 

 

 

 

50%

(HM)

 

16

 

Female

Right Ear

0.301

 

0.300

 

 

 

 

 

 

0.301± 0.0074

Left Ear

0.298

 

17

 

Female

Right Ear

0.312

 

0.311

Left Ear

0.309

 

18

 

Female

Right Ear

0.305

 

0.304

Left Ear

0.303

 

19

 

Female

Right Ear

0.291

 

0.291

Left Ear

0.290

 

20

 

Female

Right Ear

0.299

 

0.298

Left Ear

0.297

Key: mm-Millimeter, LM-Low Mid, HM-High Mid

 

Group

Dose

Animal Number

 

Sex

Site of Application

Ear Thickness (mm)

 

Mean

Mean±SD

 

 

 

 

 

 

 

5

 

 

 

 

 

 

100% (H)

 

21

 

Female

Right Ear

0.317

 

0.316

 

 

 

 

 

 

0.307 ± 0.0064

Left Ear

0.314

 

22

 

Female

Right Ear

0.302

 

0.301

Left Ear

0.300

 

23

 

Female

Right Ear

0.311

 

0.310

Left Ear

0.308

 

24

 

Female

Right Ear

0.302

 

0.301

Left Ear

0.299

 

25

 

Female

Right Ear

0.311

 

0.310

Left Ear

0.308

 

 

 

 

 

 

 

6

 

 

 

 

 

 

25%

(PC)

26

Female

Right Ear

0.552

 

0.552

 

 

 

 

 

 

0.541± 0.0140

Left Ear

0.551

 

27

 

Female

Right Ear

0.528

 

0.526

Left Ear

0.524

 

28

 

Female

Right Ear

0.561

 

0.560

Left Ear

0.558

29

 

Female

Right Ear

0.537

 

0.536

Left Ear

0.535

 

30

 

Female

Right Ear

0.533

 

0.532

Left Ear

0.531

Key: mm-Millimeter, H-High, PC-Positive Control

Table 6: Ear thickness on Day 6

Group

Dose

Animal Number

Sex

Site ofApplication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

1

 

 

 

 

 

 

0% (NC)

 

01

 

Female

Right Ear

0.284

 

0.283

 

 

 

 

 

 

 

0.285±0.0093

Left Ear

0.282

 

02

 

Female

Right Ear

0.300

 

0.300

Left Ear

0.299

 

03

 

Female

Right Ear

0.277

 

0.276

Left Ear

0.275

 

04

 

Female

Right Ear

0.279

 

0.278

Left Ear

0.277

 

05

 

Female

Right Ear

0.288

 

0.287

Left Ear

0.286

 

 

 

 

 

 

 

2

 

 

 

 

 

 

10%

(L)

 

06

 

Female

Right Ear

0.289

 

0.288

 

 

 

 

 

 

 

0.288±0.0064

Left Ear

0.287

 

07

 

Female

Right Ear

0.297

 

0.296

Left Ear

0.295

 

08

 

Female

Right Ear

0.300

 

0.299

Left Ear

0.298

 

09

 

Female

Right Ear

0.294

 

0.293

Left Ear

0.292

 

10

 

Female

Right Ear

0.306

 

0.305

Left Ear

0.304

Key: mm-Millimeter; NC-Negative Control, L-Low

Group

Dose

Animal Number

Sex

Site ofApplication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

3

 

 

 

 

 

25%

(LM)

 

11

 

Female

Right Ear

0.299

 

0.298

 

 

 

 

 

 

 

0.306 ± 0.0081

Left Ear

0.297

 

12

 

Female

Right Ear

0.314

 

0.313

Left Ear

0.311

 

13

 

Female

Right Ear

0.317

 

0.316

Left Ear

0.314

 

14

 

Female

Right Ear

0.298

 

0.297

Left Ear

0.295

 

15

 

Female

Right Ear

0.307

 

0.306

Left Ear

0.304

 

 

 

 

 

 

 

4

 

 

 

 

 

 

50%

(HM)

 

16

 

Female

Right Ear

0.304

 

0.303

 

 

 

 

 

 

 

0.303± 0.0075

Left Ear

0.301

 

17

 

Female

Right Ear

0.314

 

0.313

Left Ear

0.312

 

18

 

Female

Right Ear

0.308

 

0.307

Left Ear

0.306

 

19

 

Female

Right Ear

0.294

 

0.293

Left Ear

0.292

 

20

 

Female

Right Ear

0.302

 

0.301

Left Ear

0.299

Key: mm-Millimeter, LM-Low Mid, HM-High Mid

Group

Dose

AnimalNumber

Sex

Site ofApplication

Ear Thickness (mm)

Mean

Mean±SD

 

 

 

 

 

 

 

5

 

 

 

 

 

 

100%

(H)

 

21

 

Female

Right Ear

0.319

 

0.318

 

 

 

 

 

 

 

0.310±0.0062

Left Ear

0.316

 

22

 

Female

Right Ear

0.305

 

0.304

Left Ear

0.302

 

23

 

Female

Right Ear

0.314

 

0.313

Left Ear

0.311

 

24

 

Female

Right Ear

0.305

 

0.304

Left Ear

0.302

 

25

 

Female

Right Ear

0.314

 

0.313

Left Ear

0.311

 

 

 

 

 

 

 

6

 

 

 

 

 

 

25%

(PC)

 

26

 

Female

Right Ear

0.555

 

0.554

 

 

 

 

 

 

 

0.544±0.0140

Left Ear

0.553

 

27

 

Female

Right Ear

0.531

 

0.530

Left Ear

0.528

 

28

 

Female

Right Ear

0.564

 

0.563

Left Ear

0.561

 

29

 

Female

Right Ear

0.541

 

0.540

Left Ear

0.539

 

30

 

Female

Right Ear

0.535

 

0.534

Left Ear

0.532

Key: mm-Millimeter, H-High, PC-Positive Control

Table 7: Macroscopic finding

Group

Dose

Animal Number

Sex

Mode of Death

Macroscopic Finding

External

Internal

 

 

 

I

 

 

 

0% (NC)

01

Female

Terminal Sacrifice

NAD

NAD

02

Female

Terminal Sacrifice

NAD

NAD

03

Female

Terminal Sacrifice

NAD

NAD

04

Female

Terminal Sacrifice

NAD

NAD

05

Female

Terminal Sacrifice

NAD

NAD

 

 

 

 

2

 

 

 

10%

(L)

06

Female

Terminal Sacrifice

NAD

NAD

07

Female

Terminal Sacrifice

NAD

NAD

08

Female

Terminal Sacrifice

NAD

NAD

09

Female

Terminal Sacrifice

NAD

NAD

10

Female

Terminal Sacrifice

NAD

NAD

 

 

 

 

3

 

 

 

25%

(LM)

11

Female

Terminal Sacrifice

NAD

NAD

12

Female

Terminal Sacrifice

NAD

NAD

13

Female

Terminal Sacrifice

NAD

NAD

14

Female

Terminal Sacrifice

NAD

NAD

15

Female

Terminal Sacrifice

NAD

NAD

 

 

 

 

4

 

 

 

50%

(HM)

16

Female

Terminal Sacrifice

NAD

NAD

17

Female

Terminal Sacrifice

NAD

NAD

18

Female

Terminal Sacrifice

NAD

NAD

19

Female

Terminal Sacrifice

NAD

NAD

20

Female

Terminal Sacrifice

NAD

NAD

Note:Dose expressed in concentration (%)

Key: NC-Negative control, L-Low, LM-Low Mid, HM-High Mid, NAD- No Abnormality Detected

Group

Dose

Animal Number

Sex

Mode of Death

Macroscopic Finding

External

Internal

 

 

 

5

 

 

100%

(H)

21

Female

Terminal Sacrifice

NAD

NAD

22

Female

Terminal Sacrifice

NAD

NAD

23

Female

Terminal Sacrifice

NAD

NAD

24

Female

Terminal Sacrifice

NAD

NAD

25

Female

Terminal Sacrifice

NAD

NAD

 

 

 

 

 

 

 

6

 

 

 

 

 

 

25%

(PC)

 

26

 

Female

 

Terminal Sacrifice

Ears (Bilateral)- Reddened, slightly

Auricular lymph node (Bilateral)-

enlarged,slightly

 

27

 

Female

 

Terminal Sacrifice

Ears (Bilateral)- Reddened, slightly

Auricularlymph

node (Bilateral) - enlarged,slightly

 

28

 

Female

 

Terminal Sacrifice

Ears (Bilateral)- Reddened, slightly

Auricularlymph

node (Bilateral)-

enlarged,slightly

 

29

 

Female

 

Terminal Sacrifice

Ears (Bilateral)- Reddened, slightly

Auricularlymphnode (Bilateral) - enlarged,slightly

 

30

 

Female

 

Terminal Sacrifice

Ears (Bilateral)- Reddened, slightly

Auricularlymph

node (Bilateral) - enlarged,slightly

Note:Dose expressed in concentration (%)

Key: H- High, PC- Positive Control, NAD- No Abnormality Detected

Table 8: Organ weight

Group

Dose

Animal Number

Sex

Auricular Lymph nodes (gram)

 

 

1

 

 

0% (NC)

01

Female

0.0069

02

Female

0.0072

03

Female

0.0064

04

Female

0.0069

05

Female

0.0054

 

 

2

 

 

10% (L)

06

Female

0.0061

07

Female

0.0065

08

Female

0.0076

09

Female

0.0068

10

Female

0.0059

 

 

3

 

 

25%

(LM)

11

Female

0.0074

12

Female

0.0063

13

Female

0.0071

14

Female

0.0068

15

Female

0.0057

 

 

4

 

 

50%

(HM)

16

Female

0.0059

17

Female

0.0066

18

Female

0.0069

19

Female

0.0079

20

Female

0.0082

 

 

5

 

 

100%

(H)

21

Female

0.0068

22

Female

0.0071

23

Female

0.0083

24

Female

0.0072

25

Female

0.0069

 

 

 

6

 

 

25% (PC)

26

Female

0.0137

27

Female

0.0124

28

Female

0.0129

29

Female

0.0141

30

Female

0.0133

Key: NC-Negative control, L-Low, LM-Low Mid, HM- High Mid, H- High, PC- Positive Control

Table 9: BrDU ELISA reading

Group

Dose

Animal Number

Sex

OD Readings

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

0% (NC)

 

01

 

Female

0.242

0.234

0.224

 

02

 

Female

0.232

0.238

0.245

 

03

 

Female

0.206

0.199

0.201

 

04

 

Female

0.198

0.207

0.210

 

05

 

Female

0.188

0.179

0.191

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

10% (L)

 

06

 

Female

0.236

0.229

0.245

 

07

 

Female

0.228

0.224

0.233

 

08

 

Female

0.258

0.241

0.245

 

09

 

Female

0.217

0.208

0.203

 

10

 

Female

0.216

0.211

0.224

 

 

 

 

 

 

 

3

 

 

 

 

 

 

 

25% (LM)

 

11

 

Female

0.261

0.253

0.254

 

12

 

Female

0.247

0.236

0.231

 

13

 

Female

0.228

0.232

0.234

 

14

 

Female

0.237

0.243

0.241

 

15

 

Female

0.223

0.214

0.217

Key: NC-Negative Control, L- Low, Low Mid

Group

Dose

Animal Number

Sex

OD Readings

 

 

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

50%

(HM)

 

16

 

Female

0.242

0.236

0.229

 

17

 

Female

0.224

0.219

0.231

 

18

 

Female

0.252

0.259

0.264

 

19

 

Female

0.233

0.226

0.239

 

20

 

Female

0.229

0.248

0.241

 

 

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

100%

(H)

 

21

 

Female

0.261

0.269

0.254

 

22

 

Female

0.258

0.243

0.247

 

23

 

Female

0.227

0.234

0.236

 

24

 

Female

0.243

0.239

0.248

 

25

 

Female

0.251

0.242

0.239

Key: HM- High Mid, H-High

Group

Dose

Animal Number

Sex

OD Readings

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

25% (PC)

 

26

 

Female

0.860

0.883

0.878

 

27

 

Female

0.869

0.843

0.830

 

28

 

Female

0.962

0.953

0.909

 

29

 

Female

0.767

0.754

0.757

 

30

 

Female

0.794

0.797

0.778

Key: PC-Positive Control

Table 10: LLNA-BrDU ELISA mean readings

Animal No.

Mean OD

value

AnimalNo.

Mean OD

value

AnimalNo.

Mean OD value

AnimalNo.

Mean OD

value

Gl

G2

G3

G4

01

0.233

06

0.237

11

0.256

16

0.236

02

0.238

07

0.228

12

0.238

17

0.225

03

0.202

08

0.248

13

0.231

18

0.258

04

0.205

09

0.209

14

0.240

19

0.233

05

0.186

10

0.217

15

0.218

20

0.239

Key: OD=OpticalDensity

 

Animal No.

Mean OD value

Animal No.

Mean OD value

GS

G6

21

0.261

26

0.874

22

0.249

27

0.847

23

0.232

28

0.941

24

0.243

29

0.759

25

0.244

30

0.790

Key: OD=OpticalDensity

GI-Negative Control, G2-Low, G3-Low Mid, G4-High Mid, GS-High, G6-Positive Control

Table 11: Stimulation index

Group

Animal No.

SI value

Mean±SD

Minimum

Maximum

 

 

 

G2

06

1.113

 

 

 

1.070 ± 0.0729

 

 

 

0.981

 

 

 

1.164

07

1.071

08

1.164

09

0.981

10

1.019

 

 

 

G3

11

1.202

 

 

 

1.111 ± 0.0650

 

 

 

1.023

 

 

 

1.202

12

1.117

13

1.085

14

1.127

15

1.023

 

 

 

G4

16

1.108

 

 

 

1.119 ± 0.0575

 

 

 

1.056

 

 

 

1.211

17

1.056

18

1.211

19

1.094

20

1.122

 

 

 

GS

21

1.225

 

 

 

1.154 ± 0.0494

 

 

 

1.089

 

 

 

1.225

22

1.169

23

1.089

24

1.141

25

1.146

 

 

 

G6

26

4.103

 

 

 

3.955 ± 0.3357

 

 

 

3.563

 

 

 

4.418

27

3.977

28

4.418

29

3.563

30

3.709

Key: G2-Low, G3-Low Mid, G4-High Mid, GS-High, G6-Positive Control

Table 12: Pre-test

(1) Ear thickness on Day 1

Group

Dose

Animal Number

Sex

Site of Aoolication

Ear Thickness (mm)

Mean

Mean±SD

 

 

1

 

 

10%

 

01

 

 

Female

Right Ear

0.298

 

0.298

 

 

0.301± 0.0053

Left Ear

0.297

 

02

Right Ear

 

0.306

 

0.305

Left Ear

0.304

 

 

2

 

 

25%

 

03

 

 

Female

Right Ear

0.319

 

0.318

 

 

0.313± 0.0067

Left Ear

0.316

 

04

Right Ear

 

0.309

 

0.308

Left Ear

0.307

 

 

3

 

 

50%

 

05

 

 

Female

Right Ear

0.305

 

0.306

 

 

0.313± 0.0095

Left Ear

0.307

 

06

Right Ear

 

0.321

 

0.320

Left Ear

0.318

 

 

4

 

 

100%

 

07

 

 

Female

Right Ear

0.299

 

0.299

 

 

0.300 ±.0021

Left Ear

0.298

 

08

Right Ear

 

0.302

 

0.302

Left Ear

0.301

Key: mm-Millimeter

(2) Ear thickness on Day 3

Group

Dose

Animal Number

Sex

Site ofApplication

Ear Thickness (mm)

Mean

Mean±SD

 

 

1

 

 

10%

 

01

 

 

Female

Right Ear

0.300

 

0.300

 

 

0.303 ± 0.0046

Left Ear

0.299

 

02

Right Ear

0.307

 

0.306

Left Ear

0.305

 

 

2

 

 

25%

 

03

 

 

Female

Right Ear

0.321

 

0.320

 

 

0.315 ± 0.0071

Left Ear

0.318

 

04

Right Ear

0.311

 

0.310

Left Ear

0.308

 

 

3

 

 

50%

 

05

 

 

Female

Right Ear

0.308

 

0.309

 

 

0.316 ± 0.0092

Left Ear

0.310

 

06

Right Ear

0.323

 

0.322

Left Ear

0.321

 

 

4

 

 

100%

 

07

 

 

Female

Right Ear

0.302

 

0.302

 

 

0.303 ± 0.0014

Left Ear

0.301

 

08

Right Ear

0.304

 

0.304

Left Ear

0.303

Key: mm-Millimeter

(3) Ear thickness on Day 6

 

Group

 

Dose

Animal Number

 

Sex

Site ofApplication

Ear Thickness (mm)

 

Mean

 

Mean±SD

 

 

l

 

 

10%

 

01

 

 

Female

Right Ear

0.303

 

0.302

 

 

0.305 ± 0.0046

Left Ear

0.300

 

02

Right Ear

0.309

 

0.308

Left Ear

0.307

 

 

2

 

 

25%

 

03

 

 

Female

Right Ear

0.323

 

0.322

 

 

0.317± 0.0067

Left Ear

0.321

 

04

Right Ear

0.314

 

0.313

Left Ear

0.311

 

 

3

 

 

50%

 

05

 

 

Female

Right Ear

0.312

 

0.312

 

 

0.318±0.0014

Left Ear

0.311

 

06

Right Ear

0.326

 

0.325

Left Ear

0.324

 

 

4

 

 

100%

 

07

 

 

Female

Right Ear

0.305

 

0.304

 

 

0.305 ± 0.0014

Left Ear

0.303

 

08

Right Ear

0.307

 

0.306

Left Ear

0.305

Key: mm-Millimeter

Table 14: Body weight

 

Group

 

Dose

Animal Number

 

Sex

Test Day 1 (pre-treatment)

(g)

Test Day 6(Necropsy)(g)

 

1

 

10%

01

Female

20.74

22.28

 

02

 

Female

 

21.16

 

23.18

 

2

 

25%

03

Female

20.10

21.32

 

04

 

Female

 

20.59

 

21.75

 

3

 

50%

05

Female

19.95

21.42

 

06

 

Female

 

21.23

 

22.85

 

4

 

100%

07

Female

20.16

21.92

 

08

 

Female

 

20.64

 

22.53

Note: g-gram

Table 15: Clinical signs

 

Group

 

Dose

Animal Number

 

Sex

Test day

1

2

3

4

5

6

 

I

 

10%

01

Female

1

1

1

1

1

1

1

1

1

02

Female

l

1

I

1

1

1

1

1

1

 

2

 

25%

03

Female

1

1

1

1

I

l

1

1

1

04

Female

1

1

1

1

1

1

1

1

1

 

3

 

50%

05

Female

1

1

l

1

1

1

1

1

1

06

Female

1

1

1

1

1

1

1

1

1

 

4

 

100%

07

Female

1

l

1

1

1

1

1

1

1

08

Female

1

1

1

1

1

1

1

1

1

Key: l= Normal

Table 16: Dose foprmulation (pre-test)

 

Group

 

Name

Test Substance/Reference

Substance Quantity

 

Vehicle (DMSO)

Final Concentration

(%)

1

Low dose

100mg

1000 µI

10

2

Low mid

250mg

1000 µl

25

3

High mid

500mg

1000 µI

50

4

High dose

1000 mg

1000 µI

100

Note: DMSO- Dimethyl Sulphoxide

Table 17: Irritation scoring

 

Group

 

Dose

AnimalNumber

 

Sex

Site ofApplication

Observation day

1

2

3

4

5

6

 

 

1

 

 

10%

 

01

 

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

02

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

 

2

 

 

25%

 

03

 

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

04

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

 

3

 

 

50%

 

05

 

 

Female

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

06

Right Ear

0

0

0

0

0

0

Left Ear

0

0

0

0

0

0

 

 

4

 

 

100%

 

07

 

 

Female

Right Ear Left Ear

0

0

0

0

0

0

0

0

0

0

0

0

 

08

 

Right Ear Left Ear

0

0

0

0

0

0

0

0

0

0

0

0

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
Under the study conditions, the test substance was not skin sensitizing.
Executive summary:

A study was conducted to determine the skin sensitisation potential of the test substance according to OECD Guideline 442B (Local Lymph Node Assay: BrdU -ELISA method), in compliance with GLP. Healthy animals were allocated to six groups, each consisting of five female BALB/c mice. Animals in Group 1 (GI) were applied with vehicle (DMSO) and served as negative control (NC). The test substance was applied to both ears at the concentrations of 10% (low), 25% (low mid), 50% (high mid) and 100% (high) for dose groups G2, G3, G4 and G5, respectively. In addition, animals in Group 6 (positive control) received the reference substance eugenol (25%) in acetone: olive oil (4:1). The dorsum of both ears was used as treatment site. The animals were observed for mortality at least twice daily during the acclimatization, treatment and observation days and at least once on day of receipt and sacrifice. Body weights were recorded on test Day 1 (prior to test substance administration) and Day 6. The animals were observed for clinical signs once daily during the acclimatization period, twice daily i.e., approximately at 1 and 4 h after test substance administration on test Days 1, 2, 3, 5 and once on Days 4 and 6. The skin reactions (both ears) and ear thickness were measured on Days 1 to 6 and Days 1, 3 and 6, respectively. All animals were necropsied and examined macroscopically at the end of the observation period. The auricular lymph nodes were collected from both ears and analyzed with BrdU ELISA. All animals appeared normal throughout the acclimatization and experimental periods. Bodyweight was within the normal range of variability commonly recorded for this species, strain and age. No erythema was observed prior to the administration period. The vehicle did not cause any erythema in the negative control group. The test substance also did not induce any erythema in the low, low mid, high mid and high dose groups from Days 1 to 6. In the positive control group, all the animals showed well defined erythema on both the ears from Days 2 to 6. Ear thickness in the treated group animals was comparable with that of the negative control group, whereas ear thickness was slightly increased in the positive control group. At necropsy, no abnormalities were observed externally and internally in the negative control, low, low mid, high mid and high dose group animals, whereas externally ears (bilateral) were found to be reddened slightly and internally the size of the auricular lymph nodes (bilateral) was slightly increased in the positive control group in gross pathology. BrdU ELISA measurement with the positive control cell suspension of auricular lymph nodes resulted in a Stimulation Index (SI) value of 3.954. As the SI was greater than 1.6, sensitivity and validity of the test system were confirmed. BrdU ELISA measurement with treated groups (G2 to G5) resulted in SI of 1.070 - 1.154. As SI were less than 1.6, the test substance was considered to have no sensitization potential in the test system. Under the study conditions, the test substance was not sensitising to mouse skin (Madhu, 2020).